547 related articles for article (PubMed ID: 27092341)
1. Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.
Owsley J; Jimeno A; Diamond JR
Drugs Today (Barc); 2016 Feb; 52(2):119-29. PubMed ID: 27092341
[TBL] [Abstract][Full Text] [Related]
2. Targeting breast cancer with CDK inhibitors.
Mayer EL
Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Scott SC; Lee SS; Abraham J
Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
5. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
8. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
Chen F; Liu C; Zhang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of CDK4/6 inhibitor for breast cancer.
Iwata H
Breast Cancer; 2018 Jul; 25(4):402-406. PubMed ID: 29392622
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
Vidula N; Rugo HS
Clin Breast Cancer; 2016 Feb; 16(1):8-17. PubMed ID: 26303211
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.
Ettl J; Harbeck N
Expert Rev Anticancer Ther; 2017 Aug; 17(8):661-668. PubMed ID: 28649895
[TBL] [Abstract][Full Text] [Related]
12. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
13. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
[TBL] [Abstract][Full Text] [Related]
14. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
15. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
[TBL] [Abstract][Full Text] [Related]
16. Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
Clark AS; Karasic TB; DeMichele A; Vaughn DJ; O'Hara M; Perini R; Zhang P; Lal P; Feldman M; Gallagher M; O'Dwyer PJ
JAMA Oncol; 2016 Feb; 2(2):253-60. PubMed ID: 26633733
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
[TBL] [Abstract][Full Text] [Related]
18. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
Mayer EL
Clin Adv Hematol Oncol; 2015 Apr; 13(4):215-7. PubMed ID: 26352578
[No Abstract] [Full Text] [Related]
20. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]